Skip to main content
. Author manuscript; available in PMC: 2019 Mar 13.
Published in final edited form as: Virology. 2018 Oct 5;525:205–215. doi: 10.1016/j.virol.2018.09.019

Fig. 7. TA-HPV boosted pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine-induced HPV16 E7-specific CD8+ T cell responses through skin scarification generated the strongest antitumor immunity against established HPV16 E7-expressing cervicovaginal tumors.

Fig. 7.

A. Schematic illustration of the experiment. Briefly, groups of 5–8-week old female C57BL/6 mice (5 mice/group) were challenged with 2 × 104 of TC-1/luciferase cells intravaginally to establish cervicovaginal tumor. One day later, the mice were vaccinated with 25 μg/mouse of pNGVL4a-Sig/E7(detox)/HSP70 via intramuscular injection (hind leg muscle for DDD, DDV-SS tail, and front leg for DDV-SS ear). The mice were boosted as indicated in the figure at 4-day intervals. Expression of luciferase by TC-1 tumor cells was monitored with luminescence imaging at indicated time points. B. Luminescence imaging data from each group 14 days after tumor challenge. C. Kaplan-Meier survival analysis of TC-1/luciferase tumor cell challenged mice treated with the different regimens. * = p < 0.05.